The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Voyager Therapeutics (VYGR) has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 amyotrophic ...

Voyager Therapeutics said it will assess alternate payloads related to its gene therapeutic program related to a form of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The Type ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Roy and his wife, Jamie, asked Wake County to offer that lump sum to officers like him who medically retire but don’t ...